All Pharma News
Aulos Au-007 Interim Positive: Phase 1/2 Data At Asco 2024

Aulos Au-007 Interim Positive: Phase 1/2 Data At Asco 2024
BUSINESSWIRE
23 May 2024
Share Share
Aulos, Merck KGaA Collaborate On Bavencio + AU-007 Combo

Aulos, Merck KGaA Collaborate On Bavencio + AU-007 Combo
BUSINESSWIRE
15 May 2024
Share Share
First Patient Dosed in Phase 2 Portion of Aulos’ Phase 1/2 Trial for AU-007

First Patient Dosed in Phase 2 Portion of Aulos’ Phase 1/2 Trial for AU-007
BUSINESSWIRE
25 Jan 2024
Share Share
New Phase 1 Data for Aulos Bioscience’s AU-007 Show Favorable Pharmacodynamic

New Phase 1 Data for Aulos Bioscience’s AU-007 Show Favorable Pharmacodynamic
BUSINESSWIRE
14 Oct 2023
Share Share
Aulos Announces Presentation of Updated Safety and Efficacy Data From AU-007

Aulos Announces Presentation of Updated Safety and Efficacy Data From AU-007
BUSINESSWIRE
27 Sep 2023
Share Share
Aulos Raises $20M in Series A Extension Financing From Apple Tree Partners

Aulos Raises $20M in Series A Extension Financing From Apple Tree Partners
BUSINESSWIRE
01 Aug 2023
Share Share
Inovio prunes headcount again; Aulos adds to Series A

Inovio prunes headcount again; Aulos adds to Series A
Drew Armstrong ENDPTS
01 Aug 2023
Share Share
Interim Results From Phase 1/2 Clinical Trial in Solid Tumor Cancers Demonstrate Aulos Bioscience’s AU-007 is Well Tolerated

Interim Results From Phase 1/2 Clinical Trial in Solid Tumor Cancers Demonstrate Aulos Bioscience’s AU-007 is Well Tolerated
BUSINESSWIRE
25 May 2023
Share Share
Aulos Bioscience begins US subject dosing in solid tumours therapy trial

Aulos Bioscience begins US subject dosing in solid tumours therapy trial
CLINICAL TRIALS ARENA
02 Feb 2023
Share Share
First U.S. Patient Dosed in Aulos Bioscience’s Phase 1/2 Trial of AU-007

First U.S. Patient Dosed in Aulos Bioscience’s Phase 1/2 Trial of AU-007
BUSINESSWIRE
01 Feb 2023
Share Share